Prothena Announces $100 Million Share Repurchase Program

Prothena ( (PRTA) ) has shared an announcement.

On February 27, 2026, Prothena announced that its board had authorized a share repurchase plan allowing the company to buy back up to $100 million of its ordinary shares, with the program running through December 31, 2026 and able to be suspended or discontinued at any time. The company, which reported $308.4 million in cash, cash equivalents and restricted cash and no debt as of December 31, 2025, said repurchases will depend on market and business conditions and noted it expects to end 2026 with about $255 million in cash excluding any buybacks, while also highlighting potential milestone payments from partners Novo Nordisk and Bristol Myers Squibb that could further bolster its financial position and capital allocation flexibility.

The repurchase authorization underscores Prothena’s confidence in its balance sheet and late-stage pipeline, signaling to investors that it sees value in its equity while retaining discretion over if and when to execute buybacks. For stakeholders, the plan introduces the possibility of enhanced shareholder returns and reduced share count over time, without constraining the company’s ability to fund ongoing clinical development in neurodegenerative and amyloid diseases or respond to changing market dynamics.

The most recent analyst rating on (PRTA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Spark’s Take on PRTA Stock

According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.

Prothena’s overall stock score is primarily impacted by its financial challenges, including negative profitability and cash flows. While technical indicators show some positive momentum, the valuation remains a significant concern due to ongoing losses. The recent corporate event provides a positive outlook for financial flexibility, but strategic improvements are necessary for long-term growth.

To see Spark’s full report on PRTA stock, click here.

More about Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on investigational therapeutics targeting protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. Its pipeline, which includes both wholly owned and partnered programs, addresses conditions such as Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, ALS and other neurodegenerative disorders, and leverages its proprietary CYTOPE technology for intracellular targets.

Average Trading Volume: 577,436

Technical Sentiment Signal: Strong Sell

Current Market Cap: $482.9M

Learn more about PRTA stock on TipRanks’ Stock Analysis page.